Read-Gene Statistics

Total Valuation

Read-Gene has a market cap or net worth of PLN 66.02 million. The enterprise value is 65.43 million.

Market Cap	66.02M
Enterprise Value	65.43M

Important Dates

The last earnings date was Monday, August 11, 2025.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Read-Gene has 11.79 million shares outstanding.

Current Share Class	1.49M
Shares Outstanding	11.79M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.16%
Owned by Institutions (%)	n/a
Float	1.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.36
PB Ratio	22.64
P/TBV Ratio	22.64
P/FCF Ratio	13.83
P/OCF Ratio	12.92
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 90.80, with an EV/FCF ratio of 13.71.

EV / Earnings	-157.21
EV / Sales	4.32
EV / EBITDA	90.80
EV / EBIT	232.80
EV / FCF	13.71

Financial Position

The company has a current ratio of 1.87, with a Debt / Equity ratio of 2.71.

Current Ratio	1.87
Quick Ratio	1.87
Debt / Equity	2.71
Debt / EBITDA	10.97
Debt / FCF	1.66
Interest Coverage	0.85

Financial Efficiency

Return on equity (ROE) is -13.27% and return on invested capital (ROIC) is 1.62%.

Return on Equity (ROE)	-13.27%
Return on Assets (ROA)	1.14%
Return on Invested Capital (ROIC)	1.62%
Return on Capital Employed (ROCE)	2.60%
Revenue Per Employee	841,064
Profits Per Employee	-23,124
Employee Count	30
Asset Turnover	0.98
Inventory Turnover	201.00

Taxes

In the past 12 months, Read-Gene has paid 531,321 in taxes.

Income Tax	531,321
Effective Tax Rate	461.64%

Stock Price Statistics

The stock price has decreased by -2.62% in the last 52 weeks. The beta is 0.67, so Read-Gene's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-2.62%
50-Day Moving Average	4.96
200-Day Moving Average	4.72
Relative Strength Index (RSI)	70.30
Average Volume (20 Days)	1,922

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Read-Gene had revenue of PLN 15.14 million and -416,226 in losses.

Revenue	15.14M
Gross Profit	14.20M
Operating Income	281,074
Pretax Income	115,095
Net Income	-416,226
EBITDA	720,639
EBIT	281,074
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 8.50 million in cash and 7.91 million in debt, giving a net cash position of 589,064 or 0.05 per share.

Cash & Cash Equivalents	8.50M
Total Debt	7.91M
Net Cash	589,064
Net Cash Per Share	0.05
Equity (Book Value)	2.92M
Book Value Per Share	n/a
Working Capital	5.11M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.11 million and capital expenditures -337,733, giving a free cash flow of 4.77 million.

Operating Cash Flow	5.11M
Capital Expenditures	-337,733
Free Cash Flow	4.77M
FCF Per Share	0.40

Full Cash Flow Statement

Margins

Gross margin is 93.82%, with operating and profit margins of 1.86% and -2.75%.

Gross Margin	93.82%
Operating Margin	1.86%
Pretax Margin	0.76%
Profit Margin	-2.75%
EBITDA Margin	4.76%
EBIT Margin	1.86%
FCF Margin	31.53%

Dividends & Yields

Read-Gene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-0.63%
FCF Yield	7.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5